Vasomune Therapeutics, Inc. is a private clinical-stage biopharmaceutical company developing the next generation of medicines to harness the body’s ability to defend against illness and focused on the unique therapeutic strategy of normalizing the vasculature.
Vasomune’s lead investigational medicine AV-001 is in Phase 2 clinical trials for the treatment of severe COVID-19 disease and ARDS and is being co-developed with AnGes, Inc. [TYO: 4563]. The predecessor discovery compound was conceived of and designed in Dr. Dan Dumont’s laboratories at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto.
In November 2021, Vasomune announced that it received US$6.4m grant from the Peer-Reviewed Medical Research Program (PRMRP) at the U.S. Department of Defense and funding up to $2.8m from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
In January 2022, Vasomune announced that it had initiated a Phase 2 clinical trial evaluating AV-001 for the treatment of severe COVID-19 disease.
Vasomune’s corporate headquarters and laboratories are located in Toronto, Canada with US offices in San Mateo, CA. For more information about the company and its product candidates, please visit www.vasomune.com.
BIOTECanada, Insights Magazine, featured Vasomune in its Fall 2021 edition: https://bit.ly/3LGQqxL